FOR ADULT PATIENTS WITH OVERT
HEPATIC ENCEPHALOPATHY (HE)
Reduction IN RISK OF OVERT HE RECURRENCE1*
Reduction IN RISK OF HE-RELATED HOSPITALIZATIONS1*
XIFAXAN has been clinically proven to reduce the risk of overt HE recurrence and HE-related hospitalizations in adults.1*
*See Study Design above.
The XIFAXAN Instant Savings Card program may provide eligible, commercially insured patients savings on their monthly copays for XIFAXAN.
Hepatic encephalopathy (HE) is a common complication of cirrhosis.2,3 Up to 50% of patients with cirrhosis develop HE, with symptoms that range from minimal to severe.2,3
Practice resources are available to support you and your HE patients.
References: 1. XIFAXAN [prescribing information]. Bridgewater, NJ: Salix Pharmaceuticals. 2. Vilstrup H, Amodio P, Bajaj J, et al. Hepatic encephalopathy in chronic liver disease: 2014 Practice Guideline by the American Association for the Study of Liver Diseases and the European Association for the Study of the Liver. Hepatology. 2014;60(2):715-735. 3. Leise MD, Poterucha JJ, Kamath PS, Kim WR. Management of hepatic encephalopathy in the hospital. Mayo Clin Proc. 2014;89(2):241-253.
You are now going to be transferred to the portal intended IBS-D for healthcare professionals.